Clinical Trial Results:
A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB)
Summary
|
|
EudraCT number |
2008-006939-13 |
Trial protocol |
FR PL |
Global completion date |
23 Jan 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Mar 2019
|
First version publication date |
16 Mar 2019
|
Other versions |
|
Summary report(s) |
Results Receipt (Clinicaltrials.gov) |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.